

RECEIVED

SEP 09 2002




OF PAPERS
ORIGINALLY FILED

TECH CENTER 1600/2900

PATENT

160-
EFSIM 6.001AUS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Egashira, et al.) Group Art Unit 1634
Appl. No. : 09/773,307)
Filed : January 31, 2001)
For : METHOD OF DETECTING)
RISK FACTOR FOR ONSET)
OF DIABETES)
Examiner : J. Souaya)
I hereby certify that this correspondence and all
marked attachments are being deposited with the
United States Postal Service as first-class mail in
an envelope addressed to: United States Patent
and Trademark Office, P.O. Box 2327,
Arlington, VA 22202, on
August 28, 2002
(Date)

Katsuhiro Arai, Reg. No. 43,315

RESPONSE TO RESTRICTION REQUIREMENT

U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202


Dear Sir:

This is in response to the communication from the Examiner mailed July 31, 2001 (Paper number 19). In response to the restriction requirement set forth in the communication, Applicant elects to prosecute Group I, Claim 2, drawn to methods for detecting a risk factor for diabetic onset by detecting an abnormality at the site encoding arginine at amino acid residue 140 of the cd38 gene. Claim 1 will be examined regardless of this election. This election is made without traverse.

No fees are believed due for the present Amendment, however, should any fees be due, please charge them to our deposit account No. 11-1410.

Respectfully submitted,
KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: August 28, 2002

By: 

Katsuhiro Arai
Registration No. 43,315
Agent of Record
Customer No. 20,995
(949) 760-0404